Multiple sclerosis DMT approvals "to double by 2012" Pharma Times ... will likely constrain the adoption of these potentially high-risk/high-reward therapies by a generally conservative neurologist prescriber base, and forecasts that, together with Biogen Idec/Abbott's emerging anti-CD-25 daclizumab, sales of ... |
